Longeveron to Release Third Quarter 2021 Financial Results and Hold Conference Call on November 12, 2021
November 08 2021 - 8:30AM
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a
clinical stage biotechnology company developing cellular therapies
for chronic aging-related and life-threatening conditions, today
announced that the Company will release its third quarter 2021
financial results on Friday, November 12, 2021 before the open of
US markets. Management will host a conference call on the same day
at 8:30 a.m. ET.
The conference call will be available via
telephone by dialing toll free 1-844-200-6205 for U.S. callers;
1-646-904-5544 for local callers; or +1 929-526-1599 for
international callers and using entry code 397367. An audio replay
of the of the call will be available through November 18, 2021.
A webcast of the call may be accessed from the
“Events & Presentations” page on the Longeveron website at
https://investors.longeveron.com/events-and-presentations/default.aspx,
where you may also pre-register for the event. The recorded webcast
will remain accessible for one year through November 12, 2022.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology
company developing cellular therapies for specific aging-related
and life-threatening conditions. The Company’s lead investigational
product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”),
which is derived from culture-expanded medicinal signaling cells
(MSCs) that are sourced from bone marrow of young, healthy adult
donors. Longeveron believes that by using the same cells that
promote tissue repair, organ maintenance, and immune system
function, it can develop safe and effective therapies for some of
the most difficult disorders associated with the aging process and
other medical disorders. Longeveron is currently sponsoring Phase 1
and 2 clinical trials in the following indications: Aging Frailty,
Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory
Distress Syndrome (ARDS), and hypoplastic left heart syndrome
(HLHS). The Company’s mission is to advance Lomecel-B and other
cell-based product candidates into pivotal Phase 3 trials, with the
goal of achieving regulatory approvals, subsequent
commercialization and broad use by the healthcare community.
Additional information about the Company is available at
www.longeveron.com.
Contact:Brendan PayneStern Investor
RelationsTel: (212) 362-1200Email: Brendan.payne@sternir.com
Source: Longeveron IncSource: LGVN
Longeveron (NASDAQ:LGVN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Longeveron (NASDAQ:LGVN)
Historical Stock Chart
From Apr 2023 to Apr 2024